OBJECTIVE: Postpartum hemor-rhage (PPH) is one of the major preventable causes of
maternal death in developing countries. Although the non-parenteral use of misoprostol is a …

Misoprostol is an effective and safe uterotonic for the prevention and treatment of postpartum
hemorrhage (PPH). A 600‐μg oral dose of misoprostol has been shown to prevent PPH in …

Objective To characterize the use of the drug misoprostol for treatment of postpartum
hemorrhage in pregnant women. Methods A descriptive observational study was carried out …

Objectives: A double blind randomized controlled trial was performed at the tertiary hospital
in Harare, Zimbabwe to compare oral misoprostol with intramuscular oxytocin in the …

Objective: To compare rectally administered misoprostol to intravenously administered
oxytocin for the management of third-stage labor. Study Design: Subjects were randomized …

Background Oxytocin, the standard of care for treatment of post-partum haemorrhage, is not
available in all settings because of refrigeration requirements and the need for intravenous …

Objective: The purpose of this study was to compare misoprostol 600 μg intrarectally with
conventional oxytocics in the treatment of third stage of labor. Study Design: In a controlled …

Background Oxytocin, the gold-standard treatment for post-partum haemorrhage, needs
refrigeration, intravenous infusion, and skilled providers for optimum use. Misoprostol, a …

Introduction: Uterotonic drugs are recommended for the prevention and treatment of
postpartum hemorrhage (PPH), and oxytocin is considered the gold standard for both …

Please cite this paper as: Bellad M, Tara D, Ganachari M, Mallapur M, Goudar S, Kodkany B,
Sloan N, Derman R. Prevention of postpartum haemorrhage with sublingual misoprostol or …